Related Experiment Video
Updated: May 16, 2026
04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Methylphenidate and manic relapse in bipolar disorders: A replication study in a nationwide claims database
Nathan Vidal1,2, Solène Frileux1,2, Nadia Younes1,3
1Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d'Adultes et d'Addictologie, Le Chesnay, France.
Journal of Psychopharmacology (Oxford, England)
|May 14, 2026
Summary
Methylphenidate use in adults with bipolar disorder (BD) was studied. In patients not on mood stabilizers, methylphenidate was linked to increased mania risk, possibly due to illness progression, while those on mood stabilizers showed no significant risk increase, except at high doses.
Area of Science:
- Psychiatry
- Pharmacology
- Epidemiology
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is often comorbid with bipolar disorder (BD).
- Previous research suggested methylphenidate monotherapy increases manic relapse risk in adults with BD.
- Combination therapy with mood stabilizers may mitigate this risk.
Purpose of the Study:
- To replicate findings on methylphenidate's association with manic relapse in adults with BD.
- To investigate the risk of manic relapse when methylphenidate is prescribed alone versus with mood stabilizers.
Main Methods:
- Utilized the French national healthcare claims database (SNDS) from 2008-2024.
- Identified adults diagnosed with BD.
- Employed self-controlled survival analysis to compare manic relapse rates before and after methylphenidate initiation.
Main Results:
- In BD patients not on mood stabilizers, a significant increase in inpatient mania diagnoses occurred within 3 months of methylphenidate initiation.
- This significance was not observed in self-controlled case-crossover analyses, suggesting potential confounding by illness progression.
- BD patients on continuous mood-stabilizing treatment showed no significant increase in mania risk, except at methylphenidate doses exceeding 30 mg.
Conclusions:
- Methylphenidate is associated with manic relapse in treated BD patients only at high doses (>30 mg).
- The observed risk in untreated BD patients may reflect the natural course of mania rather than a drug effect.
- Self-controlled survival analysis has inherent limitations for this type of research.
Related Concept Videos
01:30Bipolar Disorder
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...